The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
fyi...
Stop Using Innova Medical Group SARS-CoV-2 Antigen Rapid
https://www.fda.gov › safety-communications › stop-us...
10 Jun 2021 — On April 23, 2021, Innova Medical Group recalled their Innova Medical Group SARS-CoV-2 Antigen Rapid Qualitative Test. The FDA has identified ...
How Innova got billions selling COVID tests to UK government
https://www.latimes.com › business › story › innova-pa...
28 Jul 2021 — Innova Medical Group in Pasadena secured contracts worth at least $2.7 billion selling Chinese-made antigen tests to the U.K. government ...
U.K. doubles down on Innova's rapid COVID-19 test, after FDA ...
https://www.fiercebiotech.com › medtech › u-k-doubles...
18 Jun 2021 — A week after the FDA urged anyone who had Innova Medical Group's COVID-19 antigen test to stop using it and toss it in the trash, ...
re... I am a massive investor of Avactor....
always so impreesive...dont you think?
Explanation from Porton Down doesn’t match experiences shared by industry & doesn’t explain legislative barriers put in place in July locking out domestic diagnostics
Industry can contact in confidence before Wed’s debate neale.hanvey.mp@parliament.uk
https://twitter.com/jnhanvey/status/1477585496670887941?s=21
This is BIG NEWS.
After December 31, 2021, the CDC will withdraw the emergency use authorization of the PCR test for COVID-19 testing. The CDC finally admitted the test does not differentiate between the flu and COVID virus.
Via the CDC website:
In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test. CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses. Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season.
This explains the disappearance of Flu cases in the US in 2020. It also inflated the COVID cases as Dr. Fauci and the DC elites knew would happen.
TRENDING: MUST WATCH: Dr. Robert Malone Drops BOMBSHELLS During Much-Anticipated Interview With Joe Rogan - Says Federal Government is "Lawless" and Actively "Violating the Nuremberg Code"
Via Europe Reloaded:
Quietly without media attention, the Centers for Disease Control and Prevention (CDC) has withdrawn the PCR process as a valid test for detecting and identifying SARS-CoV-2.
“After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only.”
The CDC admits that the PCR test cannot differentiate between SARS-CoV-2 and influenza viruses.
I reported several months ago that the “health authorities” had reached this decision but were withholding its implementation until the end of 2021. They needed the fake test to keep the fear going in order to achieve as much vaccination, and therefore as much profit, as possible.
It is extraordinary that the CDC’s withdrawal of the test received no attention from the media or politicians.
Dr. Kary Mullis, Nobel Laureate and inventor of the PCR process said several years ago that “the PCR is a process. It does not tell you that you are sick.” It was never meant to be a Covid test.
https://www.thegatewaypundit.com/2021/12/huge-cdc-withdraws-use-pcr-test-covid-finally-admits-test-can-not-differentiate-flu-covid-virus/
8 hrs ago
Yet another demonstration that to let Guardian reader ideologues using the law to push their anti-Conservative/Hatred of BoJo agenda is devastating to sensible government.
The one thing that we have learned is that it is a disaster to rely on the Chinese for ANYTHING - yet Mr Carrie prefers to upset UK high-tech industries rather than face down the Guardian readers.
Any in initiative the Government takes of any sort can be challenged by the Good Guardian Law Project as being some sort of corrupt private benefit being granted by the government to its friends rather than something that is beneficial to the UK population.
We URGENTLY need a review of the capacity of Judicial Review (and the Human Rights Act) to control and impede necessary government action - the government that is responsible to the electorate and dismissible by the electorate NOT to unelected Guardian reader judges.
12 min ago
The British companies have developed some of the best LFTs in the world. But HMG preferred to spend billions on the Innova LFT, a rebadged test from China. The FDA checked the Innova LFT and advised anyone who had some should put them in the bin.
54 min ago
The delay by the MHRA in clearing the UK tests was either gross incompetence or political interference. If a lawyer or journalist wants to get near the truth they should persuade the CEO of Avacta to reveal all, gagging order or no
from comments...much more to follow
Plans to manufacture lateral flow tests in the UK were shelved amid fears of legal challenges over the Government’s alleged “chumocracy”, it has been claimed.
In the early months of 2021, ministers called a halt to months of work with British companies that had been intended to establish an onshore manufacturing capability for the rapid Covid tests.
The result has left the UK relying on securing Chinese-made kits, with the devices currently unavailable in many parts of the country.
The shortage threatens to prevent people returning to work next week, and to hamper efforts to clamp down on the spread of omicron.
On Friday, figures in the diagnostics industry pointed to a slew of legal actions against Boris Johnson’s Government by the Good Law Project to explain the “baffling” decision not to build manufacturing capability in the UK.
The campaign organisation, which is led by Jolyon Maugham QC, a Remain-supporting barrister, uses judicial review actions in the High Court to challenge government policy and actions it disagrees with.
The group has launched cases opposing government policy on Brexit and, more recently, against procurement decisions in the pandemic response.
The scrutiny has contributed to a criticism of a “chumocracy” against senior ministers, including Matt Han****, who came under fire after a contract was awarded to a business owner who used to run a pub close to the former health secretary’s home.
Mr Han**** has strenuously denied any personal wrongdoing, while ministers more broadly have defended bypassing some civil service procurement red tape in the early stages of the pandemic due to the urgency of the crisis.
The Good Law Project is led by Jolyon Maugham QC
The Good Law Project is led by Jolyon Maugham QC Credit: Andrew Milligan/PA Wire/Andrew Milligan/PA Wire
Doris-Ann Williams, the chief executive of the British In Vitro Diagnostics Association, said that Lord Bethel, the junior health minister, had encouraged a consortium of companies to push ahead with research and development into lateral flow tests from autumn 2020, but that the drive had been scrapped in early in 2021, with no adequate reason given.
“They threw a lot of money at it and encouraged the companies to ramp up their manufacturing capability, but when it got to the crucial point the government said it was never their intention to purchase,” she said.
“For some reason they went to the Chinese.
“It’s just baffling that you would put so much effort into UK manufacturing and then turn round and say we don’t want to purchase.”
She added: “It seemed to get caught up with the Good Law Project.”
Placeholder image for youtube video: qTZzJHGhED4
Another industry insider said the episode had resulted in a “complete lack of trust” between manufacturers and the Department of Health and Social Care.
“A lot of these firms wanted to help out of a spirit of public service, but after this they won’t go near the government aga
+ an excellent 2022 in every way.
...attached for all to see....a marvellous piece of music in all respects.
The Tallis Scholars - Allegri Miserere...
https://www.youtube.com/watch?v=UFIIBBXVzuk
SCRUTABLE
22 Dec '21 - 16:14 - 40776 of 40781
0 24 0
Any investor here who has ever built a business from the beginning will be extremely excited, as I am today. Never in 70 years of business experience, all over Europe and the USA have I seen such a conjunction of favourable circumstances and appropriate assets, real and intangible, to ensure long term value growth ahead.
AVACTA's capabilities and products are just right for the times and context, and mature enough now, to reward anyone holding a piece of the action, who can control the impulse to snatch an easy instant profit. They will profit for years and years unless the management succumbs to that same weakness.
The comparative brilliance with other players in the same market, their USP as I think Tickboo recently expressed, lies in their patented development and creation of Affimers.
I am 94 and clear headed. It is contact with such inventiveness and tenacity which keeps me going, I hope for a decade still to come..
Lateral flow tests hit by 'supply chain' crisis four days before Christmas: Pharmacies hit by delivery delays as Brits scramble for swab kits before seeing family
More than 11m test kits sent out to pharmacies last week - double previous week
But many Britons are complaining they still cannot not find one anywhere locally
Some pharmacies have put up signs saying they are temporarily out of stock,
People are also struggling to order tests online amid 'unprecedented' demand
https://www.dailymail.co.uk/news/article-10331665/Lateral-flow-tests-hit-supply-chain-crisis-
https://www.medtechdive.com/news/fda-update-covid-tests-fail-detect-omicron-variant/611617/
tickboo
Half yearly update this morning. MITON hold 4.66% of Avacta across various funds. Nice to see them more positive than ever.
What were the main contributors to the Trust's return over the half year?
After the substantial outperformance of quoted microcaps in the year to April 2021, the ongoing uncertainty regarding inflation led to many investors taking profits during the half year between April and October. Hence whilst Avacta was one of the better performers in the prior period, over this half year it was the greatest detractor in the portfolio, as its share price fell due to an absence of news regarding commercial orders for its novel lateral flow test for COVID-19. Another disappointing holding was Helium One, where its share price had risen just ahead of the start of the half year in anticipation of the results of its first helium wells. Whilst these confirmed the presence of helium during the half year, the geology has proved more complex than anticipated, so Helium One's share price was notably weak. A third example is Accrol, where unreliable deliveries of its toilet tissue led to its supermarket customers refusing to fund the additional manufacturing costs, at least initially. Where the prospects for imminent cash surpluses of portfolio holdings substantially diminishes, we tend to sell the positions without delay. Interestingly, in all three of the holdings outlined above, our confidence in their imminent cash prospects haven't greatly altered. Therefore, all three of these positions remain in the portfolio, and may have even greater upside potential than previously.
‘the key thing affecting share prices is not the pandemic but the speculative activity it encourages. As two chief executives told me, once you get to a certain market cap, the mandarins at the Stock Exchange move your trading mechanism from market makers to SETS and this is where manipulation by algo traders takes place, with streams of small trades exaggerating downdraughts and triggering stoplosses'
Bronte:
"In Australian dollar terms, Bronte’s Australian “Amalthea” fund returned negative 24.3 per cent for the 12 months to March 31, 2021. Over the same period, Bronte’s benchmark, the MSCI World Index (in AUD), returned 23.9 per cent. Bronte therefore underperformed its benchmark by 48.2 per cent.
In US dollars, Bronte’s Cayman “Callisto” fund returned negative 7.5 per cent over the 12 months to March 31. The MSCI World Index (in USD) returned 54.6 per cent in the same period, so Bronte’s underperformance was 62.1 per cent."
https://microbiome-europe.com/speaker/alex-stevenson/
Alex Stevenson
Company: 4D Pharma PLC
Job title: CSO
Seminars:
Taking the Microbiome Beyond the gut – Realizing the Full Potential of Microbiome Therapies Through Targeted Systemic Effects 9:55 am
After landmark successes in C. diff, the rapidly maturing microbiome field is poised to deliver meaningful clinical data across a wider range of systemic diseases Principles for target- and mechanism-driven LBP discovery & development Successful drug development is about more than just great research – CMC, IP, Clinical & Regulatory considerationsRead more
day: Day Two
https://www.business-live.co.uk/manufacturing/green-jet-fuels-a-great-22362133
“Now this is just the start. The initial deal is for two years, and we are really hopeful we can extend with Phillips 66. The nice thing is, we have got five different projects all with different
technologies, using different ways to produce SAF. They are all from different types of waste product too.
“Velocys could be producing from 2025, that will take domestic waste that would otherwise go to landfill, so is solving two problems.”
The current total supply of SAF is 0.4 per cent, with global aviation, and a target set by BA’s parent company, International Airlines Group, is for 10 per cent by 2030.
To achieve that would mean another 50 times the Phillips 66 amount.
Https://www.bloomberg.com/news/articles/2021-12-01/cdc-confirms-first-case-of-omicron-variant-detected-in-u-s
""Testing for the infection was done by a Color Health Inc. lab in San Francisco, according to an outside representative of the company. The strain was identified in less than 30 hours from sample collection. The sample was then turned over to the University of California, San Francisco lab of Charles Chiu for confirmatory sequencing.
Chiu said his laboratory heard about the sample on Tuesday afternoon and had received it by 8 p.m. From there, they ran a quick molecular test looking for what’s known as spike-gene dropout, which suggested the sample was possibly omicron.
Small Sequencer
To confirm the finding, the lab sequenced the entire genome of the virus using a pocket-sized sequencing machine made by Oxford Nanopore Technologies PLC. Within five hours, they had confirmed the detection of omicron, and within eight, the entire genome had been decoded.
“At 4 a.m. last night we were able to conclusively demonstrate that this was indeed an infection from the omicron variant,” he said in the press conference."
https://www.sharesmagazine.co.uk/news/market/LSE20211202070006_4198805/Full-Year-Results
Strong operational and financial results ahead of expectations as we continue to support the transformation of the auction industry
Financial Highlights
• Revenue of £70.1m, a 34% increase on an aggregate basis year-on-year, with growth achieved in all six of the Group's marketplaces
• Adjusted EBITDA of £31.8m, a margin of 45%
• Loss before tax of £27.3m after share-based payments expense and charges for exceptional items, primarily related to the IPO and acquisition of LiveAuctioneers and intangible asset amortisation
• Refinancing complete, with a five-year New Senior Facilities Agreement, including a $204.0m term loan for the LiveAuctioneers acquisition and $49.0m revolving credit facility
• Strong cash generation, with £30.4m of adjusted free cash flow in the period and a closing net cash position of £24.6m
Since my last update, ATG has announced the acquisition of LiveAuctioneers, which looks transformational. LiveAuctioneers is an A&A portal with a strong US presence. It also brings into the fold an established payments business, which ATG will be able to roll out across its whole customer base - both I&C and A&A. Numis has lifted its eps forecast by 12% to 19.1p for the current year to end September. For the following year, eps rises 25% to 26.8p. Keep buying.